Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
What’s new on Haematologica.org: Check updates and related news right now. This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Haematologica.org popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.
Latest marketing authorisations and orphan drug designations Marketing authorisations and medicinal products designations Detailed information on European orphan medicinal products designation applications is available on theEMA website. A full...
COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab...
Ben Fidler As a gene therapy company, Bluebird Bio was a surprising IPO star in 2013. After all, it’s working in a field that was kicked to the curb in the previous decade. What’s more, it made its IPO pitch on the back of the slimmest amount of data...
In patients with polycythemia vera (PV), the drug Jakafi® (ruxolitinib) can help control disease at least one year. These findings were presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11–14, 2015.[1] Polycythemia...
Is It Possible to Control Cancer Without Killing It? | Jerome Groopman: Jerome Groopman on an experimental cancer drug that can transform malignant cells into healthier ones. An experimental new drug can make some leukemic cells mature into healthier...
Managing Myeloma is an educational initiative dedicated to developing tools, information, and resources that support improved ther...
WhatDoctorsAreSaying - YouTube
Share your videos with friends, family, and the world
MiniWrites – A hub for your creative projects!
A hub for your creative projects!
Open access journal of the Ferrata-Storti Foundation, a no profit organization
Sovleplenib is a selective spleen tyrosine kinase (Syk) inhibitor with anti-tumor activity in preclinical models of B-cell malignancy. Targeting Syk signaling, which is upstream of both Bruton tyrosin...
18 years
Domain age
00:01:31
Visit duration
1.5K
Daily visitors
69%
Bounce rate
N/A
Child safety
Excellent
Trust
Excellent
Privacy
40.5 %
USA